Table 1.
Baseline characteristics of patients with mCRPC
| Characteristicsa | n = 5213 |
|---|---|
| Age at mCRPC diagnosis date, years, mean [median] | 72.6 [74] |
| Race, n (%) | |
| Patients with known race | 4765 (91.4) |
| White | 3638 (76.3) |
| Others | 517 (10.8) |
| Black or African Americans | 511 (10.7) |
| Asian | 86 (1.8) |
| Hispanic or Latino | 13 (0.3) |
| Ethnicity: Hispanic or Latino, n (%) | 299 (5.7) |
| Year of mCRPC diagnosis date, n (%) | |
| 2013 | 413 (7.9) |
| 2014 | 816 (15.7) |
| 2015 | 937 (18.0) |
| 2016 | 1003 (19.2) |
| 2017 | 1070 (20.5) |
| 2018 | 847 (16.2) |
| 2019 (Q1) | 127 (2.4) |
| Patient’s region of residence, n (%) | |
| Patients with known region | 4723 (90.6) |
| South | 2383 (50.5) |
| West | 856 (18.1) |
| Northeast | 750 (15.9) |
| Midwest | 734 (15.5) |
| Practice type, n (%) | |
| Community-based | 4762 (91.3) |
| Academic | 451 (8.7) |
| Time to mCRPC diagnosis date, years, mean [median] | |
| From initial PC diagnosis | 5.8 [3] |
| From clinical activity startb | 2.2 [2] |
| PC characteristics at the initial PC diagnosis | |
| Cancer stage, n (%) | |
| Patients with stage known | 2925 (56.1) |
| Stage I–III | 641 (21.9) |
| Stage IV | 2284 (78.1) |
| Gleason score, n (%) | |
| Patients with Gleason score known | 4349 (83.4) |
| ≤ 6 (low risk) | 412 (9.5) |
| 7 (intermediate risk) | 1068 (24.6) |
| ≥ 8 (high risk) | 2869 (66.0) |
| PC characteristics at the mCRPC diagnosis datec | |
| ECOG performance status | |
| Patients with ECOG test, n (%) | 1930 (37.0) |
| ECOG score of 0–1 | 1614 (83.6) |
| ECOG score ≥ 2 | 316 (16.4) |
| Laboratory test results, mean [median] (% patients tested) | |
| Hemoglobin level (g/dL) | 12.3 [13] (58.3) |
| Lactose dehydrogenase (U/L) | 247.0 [195] (12.5%) |
| PSA laboratory value (ng/mL) | 130.9 [18] (92.8) |
| Serum albumin (g/L) | 40.1 [41] (55.3) |
| Serum alkaline phosphatase (U/L) | 146.9 [90] (56.8) |
ECOG Eastern cooperative oncology group, EHR electronic health record, mCRPC metastatic castration-resistant prostate cancer, PC prostate cancer, PSA prostate-specific antigen, SD standard deviation
aComorbid conditions are not reported in the current study because they are underreported in EHR data from oncology centers
bClinical activity included any recorded interactions between the patient and a healthcare provider, including visits, use of therapies (e.g., oral or immuno-oncology, androgen deprivation therapy, radiopharmaceuticals, medication orders, and administrations) or laboratory tests, vital assessments, ECOG performance assessments, progression events, as well as death
cEvaluated on the date closest to the mCRPC diagnosis date in the 3 months prior to or on the mCRPC diagnosis date